Abstract:4036 Background: Esophageal squamous cell carcinoma (ESCC) is the predominant histological subtype of esophageal cancer in South America and East Asian countries and remains an unmet medical need worldwide. Previous studies have shown the efficacy of programmed cell death 1 (PD-1) targeted therapy in a subset of patients with metastatic ESCC. However, robust predictive biomarkers to PD-1 antibody-based immunotherapy remain undefined. Methods: Patients included in this analysis were part of multi-center, phase Ib/II trial (NCT02915432) evaluating the safety and activity of toripalimab, a humanized PD-1 antibody in solid tumors. To identify molecular determinants of response, we performed whole exome sequencing (WES), messenger RNA sequencing and immunohistochemistry on patients’ samples and evaluated genomic and transcriptional biomarkers, PD-L1 expression and tumor mutational burden (TMB) for correlation with clinical efficacy. Results: Sixty advanced chemo-refractory ESCC patients were enrolled and 59 were treated with toripalimab. 94.9% (56/59) patients experienced at least one treatment related adverse event after 16 months; mostly grade 1 or grade 2. Treatment-related grade 3 or higher AEs occurred in 30.5% (18/59) of subjects. By the data cutoff date, 11 (18.6%; 95%CI 9.7 to 30.9) patients achieved an objective response, while the disease control rate was 47.5% (95%CI 34.3 to 60.9). Copy number analysis identified 24 out of 50 (48%) patients with amplifications of chromosome 11q13 region, which was consistent with elevated mRNA expression of amplified genes, including CCND1(Cyclin D1) and fibroblast growth factor family members ( FGF3/4/19). Patients without 11q13 amplification, had significantly better objective response rate (ORR 30.8% versus 4.2%, p= 0.024) and progression free survival (3.7 versus 2.0 months, HR = 0.47 [95%CI 0.24 to 0.91], p= 0.025) when compared with 11q13 amplified individuals. In contrast, patients with high TMB (≥12 Mutations/Mb; 11/47, 23.4%) or positive PD-L1 expression (TC or IC 1%; 19/57, 33.3%) showed no significant advantage in ORR or survival. Conclusions: Toripalimab has demonstrated a manageablesafety profile and promising anti-tumor activity in chemo-refractory ESSC patients. Genomic amplification of 11q13 region may serve as a negative predictive marker for advanced ESSC patients receiving anti-PD-1 based immunotherapy. Further interrogation of putative resistance genes that lie within this region is under study. Clinical trial information: NCT02915432.

Amplification of the Telomerase RNA Component Gene As a New Genetic Marker for Disease Progression and Prognosis in Esophageal Squamous Cell Carcinoma.

Detection of TERC Amplification in Cervical Epithelial Cells for the Diagnosis of High-Grade Cervical Lesions and Invasive Cancer: A Multicenter Study in China

[Clinical Application of Telomerase RNA Component Gene Amplification Assay in Cervical Lesions.].

Discriminating Association of a Common Telomerase Reverse Transcriptase Promoter Polymorphism with Telomere Parameters in Non-Small Cell Lung Cancer with or Without Epidermal Growth Factor Receptor Mutation.

Clinical significance of human telomerase RNA gene (hTERC) amplification in cervical squamous cell lesions detected by fluorescence in situ hybridization.

Prevalence of Gene Amplifications of Sox-2, C-Met, and Fgfr1 in Asian Patients with Esophageal Squamous Cell Carcinoma.

Genomic amplification of the human telomerase RNA gene for differential diagnosis of cervical disorders.

Human Telomerase Rna Gene Amplification Detection Increases the Specificity of Cervical Intraepithelial Neoplasia Screening

Expression and functional analyses of TERF2 in esophageal carcinoma

Telomerase RNA Gene (TERC) and Recent Studies on Cervical Cancer

Telomerase Activity and Expression of Telomerase Genes in Squamous Dysplasia and Squamous Cell Carcinoma of the Esophagus

Expression of human telomerase reverse transcriptase (hTERT) protein is significantly associated with the progression, recurrence and prognosis of oral squamous cell carcinoma in Taiwan

Aberrant Methylation of the TERT Promoter in Esophageal Squamous Cell Carcinoma.

Association of Frequent Amplification of Chromosome 11q13 in Esophageal Squamous Cell Cancer with Clinical Benefit to Immune Check Point Blockade.

Different Amplification Patterns of the Human Telomerase RNA Gene in Invasive Cervical Carcinomas and Cervical Intraepithelial Neoplasia Grade III

Protein Overexpression and Gene Amplification of EGFR in Esophageal Squamous Cell Carcinoma: Relationship Between Malignant Biologic Behavior and EGFR Status Study.

[Evaluation of Genomic Amplification of the Human Telomerase RNA Component Gene in the Screening of Cervical Lesions].

Detection and Clinical Significance of TERC Amplification in Different Cervical Lesions

Expression and significance of TERC gene in cervical tumor

TERC Promotes Non-Small Cell Lung Cancer Progression by Facilitating the Nuclear Localization of TERT

Deciphering Treg cell roles in esophageal squamous cell carcinoma: a comprehensive prognostic and immunotherapeutic analysis